Natera Inc
Research Natera Inc (NTRA) on Bullrun: market cap USD 57.12B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNTRA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyUSD
- Market capUSD 57.12B
- Financial periodQ2 2026
- RevenueUSD 752.75M
- Net income-USD 66.97M
- Free cash flow-USD 8.64M
- Gross margin64.5%
Valuation Snapshot
latest market cap is USD 57.12B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 2.31B | -USD 208.16M | USD 109.11M | 64.7% | -1.52 | USD 1.08B | USD 80.32M | USD 1.71B |
| FY2024 | USD 1.70B | -USD 190.43M | USD 69.24M | 60.3% | -1.53 | USD 945.59M | USD 80.36M | USD 1.20B |
| FY2023 | USD 1.08B | -USD 434.80M | -USD 286.15M | 45.5% | -3.78 | USD 642.10M | USD 363.35M | USD 765.33M |
| FY2022 | USD 820.22M | -USD 547.80M | -USD 479.20M | 44.4% | -5.57 | USD 466.01M | USD 362.00M | USD 705.74M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 57.12B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 32.00B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 21.00B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 7.53B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 4.45B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 8.89B | n/a | n/a | n/a |
About Natera Inc
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test.
ETFs that hold Natera Inc
Natera Inc is one of the ten largest holdings of 20 ETFs that investors in Europe can buy. The 8 most traded of them:
| ETF | Weight | TER |
|---|---|---|
| Invesco MSCI World Equal Weight UCITS ETF USD Accumulating | 0.11% | 0.20% |
| iShares Healthcare Innovation UCITS ETF USD (Acc) | 2.26% | 0.40% |
| ARK Genomic | 4.91% | 0.75% |
| Global X Genomics & Biotechnology UCITS ETF USD Acc | 4.57% | 0.50% |
| Invesco NASDAQ Next Generation 100 UCITS ETF Acc | 3.01% | 0.25% |
| iShares MSCI World Mid-Cap Equal Weight UCITS ETF | 0.29% | 0.30% |
| JPM BetaBuilders US Small Cap Equity UCITS ETF - USD (acc) | 0.61% | 0.13% |
| L&G Healthcare Technology & Innovation ETF USD Acc | 2.41% | 0.49% |
Compare every fund on the same index:
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Natera Inc's market cap?
Natera Inc's market capitalization is USD 57.12B.
What does Natera Inc do?
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test.